サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566884

加齢黄斑変性市場：薬剤タイプ別、疾患タイプ別、流通チャネル別：世界の機会分析と産業予測、2024年～2033年

Age Related Macular Degeneration Market By Drug Type , By Disease Type (Wet Age Related Macular Degeneration , Dry Age Related Macular Degeneration ) By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 216 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
加齢黄斑変性市場：薬剤タイプ別、疾患タイプ別、流通チャネル別：世界の機会分析と産業予測、2024年～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 216 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

加齢黄斑変性市場

加齢黄斑変性市場は、2023年に100億米ドルと評価され、2024年から2033年までCAGR 5%で成長し、2033年には162億米ドルに達すると予測されています。

加齢黄斑変性は、黄斑として知られる網膜の中心部分が劣化する視覚障害です。わずかなかすみ目から始まり、最終的には中心視力を失う。この病気には、乾性（萎縮性）と湿性（血管新生）の2つのカテゴリーがあります。乾性黄斑変性では黄斑が徐々に薄くなるのに対し、湿性黄斑変性は網膜下の血管が異常に増殖することで起こる。

高齢化人口の指数関数的な増加と有病率の上昇が、加齢黄斑変性市場の主要促進要因です。加えて、診断技術の進歩が病気の早期発見とタイムリーな治療につながり、市場開拓を後押ししています。最近では、AIとディープラーニングが加齢黄斑変性の診断と治療の状況に革命をもたらしています。この技術は、眼の状態を正確に検出し、病気が進行した場合のリスクを評価するのに役立ちます。

しかし、病期が高度に進行した場合、治療法は限られた効果しか示さないため、加齢黄斑変性市場の成長を抑制しています。さらに、抗血管内皮増殖因子注射のような病気を治すのに不可欠な薬剤を購入する費用が高額なため、治療を受けられない患者もいます。これが市場開拓の妨げとなっています。英国の科学雑誌出版社BioMed Centralが発表した論文によると、加齢黄斑変性は視力低下の主な原因の1つであり、2040年までに2億8,800万人に影響が及ぶと予測されています。

セグメント別レビュー

加齢黄斑変性市場は、薬剤タイプ、疾患タイプ、流通チャネル、地域に区分されます。薬剤タイプでは、アフリベルセプト、ラニビズマブ、その他に分けられます。疾患タイプ別では、湿性加齢黄斑変性（AMD）と乾性加齢黄斑変性（AMD）に二分されます。販売チャネル別では、病院薬局、小売薬局、オンライン薬局に分類されます。地域別では、北米、欧州、アジア太平洋、LAMEAで分析されています。

主な調査結果

薬剤タイプ別では、アフリベルセプトセグメントが加齢黄斑変性市場を独占しています。

疾患タイプ別では、湿性加齢黄斑変性（AMD）セグメントが市場で大きなシェアを獲得しています。

販売チャネル別では、病院薬局セグメントが市場をリードしています。

地域別では、市場は北米で力強い成長を示しています。

本レポートのカスタマイズが可能です。

  • 規制ガイドライン
  • クライアントの関心に合わせた企業プロファイルの追加
  • 企業プロファイルの拡張リスト
  • 過去の市場データ

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 加齢黄斑変性市場：薬剤タイプ別

  • 市場概要
  • アフリベルセプト
  • ラニビズマブ
  • その他

第5章 加齢黄斑変性市場：疾患タイプ別

  • 市場概要
  • 湿性加齢黄斑変性（AMD）
  • ドライ型加齢黄斑変性（AMD）

第6章 加齢黄斑変性市場：流通チャネル別

  • 市場概要
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 市場概要加齢黄斑変性市場：地域別

  • 市場概要
  • 北米
    • 主な市場動向と機会
    • 米国の加齢黄斑変性市場
    • カナダの加齢黄斑変性市場
    • メキシコ加齢黄斑変性市場
  • 欧州
    • 主要市場動向と機会
    • フランスの加齢黄斑変性市場
    • ドイツの加齢黄斑変性市場
    • イタリアの加齢黄斑変性市場
    • スペインの加齢黄斑変性市場
    • 英国の加齢黄斑変性市場
    • その他欧州の加齢黄斑変性市場
  • アジア太平洋
    • 主な市場動向と機会
    • 中国の加齢黄斑変性市場
    • 日本の加齢黄斑変性市場
    • インドの加齢黄斑変性市場
    • 韓国の加齢黄斑変性市場
    • オーストラリアの加齢黄斑変性市場
    • その他アジア太平洋の加齢黄斑変性市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルの加齢黄斑変性市場
    • 南アフリカの加齢黄斑変性市場
    • サウジアラビアの加齢黄斑変性市場
    • その他のラテンアメリカ・中東・アフリカ加齢黄斑変性市場

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第9章 企業プロファイル

  • Regeneron Pharmaceuticals Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Biogen
  • Bayer AG
  • Coherus Biosciences Inc
  • Sanofi
  • Apellis Pharmaceuticals
  • Bausch Health Companies Inc.
  • Ionis Pharmaceuticals, Inc
目次
Product Code: A201849

Age Related Macular Degeneration Market

The age related macular degeneration market was valued at $10.0 billion in 2023 and is projected to reach $16.2 billion by 2033, growing at a CAGR of 5% from 2024 to 2033.

Age related macular degeneration is a visual impairment in which the central portion of the retina, known as macula, deteriorates. Beginning with slight blurred vision, the disease eventually leads to loss of central eyesight. There are two categories of the disease: dry (atrophic) and wet (neovascular). Gradual thinning of the macula occurs in dry macular degeneration, whereas wet macular degeneration happens due to abnormal growth of blood vessels under the retina.

Exponential increase in the aging population and rise in prevalence of the disease are the key drivers of the age related macular degeneration market. In addition, advancements in diagnostic techniques are leading to early detection and timely treatment of the disease, thereby augmenting the market development. In recent times, AI and deep learning are revolutionizing the landscape of age related macular degeneration diagnosis and treatment. The technology helps in precise detection of the eye condition and assesses the risk pertaining to the progression of the disease to advanced stages.

However, in case of disease advancement to high stages, treatment procedures exhibit limited to no efficacy, thereby restraining the growth of the age related macular degeneration market. Moreover, the high expense of purchasing medications essential for curing the disease, such as anti-vascular endothelial growth factor injections, constraints several patients from undergoing the treatment. This hampers the development of the market. According to an article published by the UK-based scientific journals publisher-BioMed Central- age related macular degeneration is one of the leading causes of vision loss and by 2040, the disease is anticipated to impact 288 million individuals.

Segment Review

The age related macular degeneration market is segmented into drug type, disease type, distribution channel, and region. On the basis of drug type, the market is divided into aflibercept, ranibizumab, and others. Depending on disease type, it is bifurcated into wet age related macular degeneration (AMD) and dry age related macular degeneration (AMD). As per distribution channel, it is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of drug type, the aflibercept segment dominates the age related macular degeneration market.

Depending on disease type, the wet age-related macular degeneration (AMD) segment acquires a significant share of the market.

As per distribution channel, the hospital pharmacy segment leads in the market.

Region wise, the market exhibits robust growth in North America.

Competition Analysis

The leading players operating in the global age related macular degeneration market include Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Biogen, Bayer AG, Coherus Biosciences Inc, Sanofi, Apellis Pharmaceuticals, Bausch Health Companies Inc., and Ionis Pharmaceuticals, Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Drug Type

  • Aflibercept
  • Ranibizumab
  • Others

By Disease Type

  • Wet Age Related Macular Degeneration (AMD)
  • Dry Age Related Macular Degeneration (AMD)

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Regeneron Pharmaceuticals Inc.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Biogen
    • Bayer AG
    • Coherus Biosciences Inc
    • Sanofi
    • Apellis Pharmaceuticals
    • Bausch Health Companies Inc.
    • Ionis Pharmaceuticals, Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Drug Type
  • 4.2. Aflibercept
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Ranibizumab
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Others
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Disease Type
  • 5.2. Wet Age Related Macular Degeneration (AMD)
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Dry Age Related Macular Degeneration (AMD)
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Distribution Channel
  • 6.2. Hospital Pharmacy
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Retail Pharmacy
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Online Pharmacy
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: AGE RELATED MACULAR DEGENERATION MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Drug Type
    • 7.2.3. Market Size and Forecast, By Disease Type
    • 7.2.4. Market Size and Forecast, By Distribution Channel
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Age Related Macular Degeneration Market
      • 7.2.6.1. Market Size and Forecast, By Drug Type
      • 7.2.6.2. Market Size and Forecast, By Disease Type
      • 7.2.6.3. Market Size and Forecast, By Distribution Channel
    • 7.2.7. Canada Age Related Macular Degeneration Market
      • 7.2.7.1. Market Size and Forecast, By Drug Type
      • 7.2.7.2. Market Size and Forecast, By Disease Type
      • 7.2.7.3. Market Size and Forecast, By Distribution Channel
    • 7.2.8. Mexico Age Related Macular Degeneration Market
      • 7.2.8.1. Market Size and Forecast, By Drug Type
      • 7.2.8.2. Market Size and Forecast, By Disease Type
      • 7.2.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Drug Type
    • 7.3.3. Market Size and Forecast, By Disease Type
    • 7.3.4. Market Size and Forecast, By Distribution Channel
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Age Related Macular Degeneration Market
      • 7.3.6.1. Market Size and Forecast, By Drug Type
      • 7.3.6.2. Market Size and Forecast, By Disease Type
      • 7.3.6.3. Market Size and Forecast, By Distribution Channel
    • 7.3.7. Germany Age Related Macular Degeneration Market
      • 7.3.7.1. Market Size and Forecast, By Drug Type
      • 7.3.7.2. Market Size and Forecast, By Disease Type
      • 7.3.7.3. Market Size and Forecast, By Distribution Channel
    • 7.3.8. Italy Age Related Macular Degeneration Market
      • 7.3.8.1. Market Size and Forecast, By Drug Type
      • 7.3.8.2. Market Size and Forecast, By Disease Type
      • 7.3.8.3. Market Size and Forecast, By Distribution Channel
    • 7.3.9. Spain Age Related Macular Degeneration Market
      • 7.3.9.1. Market Size and Forecast, By Drug Type
      • 7.3.9.2. Market Size and Forecast, By Disease Type
      • 7.3.9.3. Market Size and Forecast, By Distribution Channel
    • 7.3.10. UK Age Related Macular Degeneration Market
      • 7.3.10.1. Market Size and Forecast, By Drug Type
      • 7.3.10.2. Market Size and Forecast, By Disease Type
      • 7.3.10.3. Market Size and Forecast, By Distribution Channel
    • 7.3.11. Rest of Europe Age Related Macular Degeneration Market
      • 7.3.11.1. Market Size and Forecast, By Drug Type
      • 7.3.11.2. Market Size and Forecast, By Disease Type
      • 7.3.11.3. Market Size and Forecast, By Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Drug Type
    • 7.4.3. Market Size and Forecast, By Disease Type
    • 7.4.4. Market Size and Forecast, By Distribution Channel
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Age Related Macular Degeneration Market
      • 7.4.6.1. Market Size and Forecast, By Drug Type
      • 7.4.6.2. Market Size and Forecast, By Disease Type
      • 7.4.6.3. Market Size and Forecast, By Distribution Channel
    • 7.4.7. Japan Age Related Macular Degeneration Market
      • 7.4.7.1. Market Size and Forecast, By Drug Type
      • 7.4.7.2. Market Size and Forecast, By Disease Type
      • 7.4.7.3. Market Size and Forecast, By Distribution Channel
    • 7.4.8. India Age Related Macular Degeneration Market
      • 7.4.8.1. Market Size and Forecast, By Drug Type
      • 7.4.8.2. Market Size and Forecast, By Disease Type
      • 7.4.8.3. Market Size and Forecast, By Distribution Channel
    • 7.4.9. South Korea Age Related Macular Degeneration Market
      • 7.4.9.1. Market Size and Forecast, By Drug Type
      • 7.4.9.2. Market Size and Forecast, By Disease Type
      • 7.4.9.3. Market Size and Forecast, By Distribution Channel
    • 7.4.10. Australia Age Related Macular Degeneration Market
      • 7.4.10.1. Market Size and Forecast, By Drug Type
      • 7.4.10.2. Market Size and Forecast, By Disease Type
      • 7.4.10.3. Market Size and Forecast, By Distribution Channel
    • 7.4.11. Rest of Asia-Pacific Age Related Macular Degeneration Market
      • 7.4.11.1. Market Size and Forecast, By Drug Type
      • 7.4.11.2. Market Size and Forecast, By Disease Type
      • 7.4.11.3. Market Size and Forecast, By Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Drug Type
    • 7.5.3. Market Size and Forecast, By Disease Type
    • 7.5.4. Market Size and Forecast, By Distribution Channel
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Age Related Macular Degeneration Market
      • 7.5.6.1. Market Size and Forecast, By Drug Type
      • 7.5.6.2. Market Size and Forecast, By Disease Type
      • 7.5.6.3. Market Size and Forecast, By Distribution Channel
    • 7.5.7. South Africa Age Related Macular Degeneration Market
      • 7.5.7.1. Market Size and Forecast, By Drug Type
      • 7.5.7.2. Market Size and Forecast, By Disease Type
      • 7.5.7.3. Market Size and Forecast, By Distribution Channel
    • 7.5.8. Saudi Arabia Age Related Macular Degeneration Market
      • 7.5.8.1. Market Size and Forecast, By Drug Type
      • 7.5.8.2. Market Size and Forecast, By Disease Type
      • 7.5.8.3. Market Size and Forecast, By Distribution Channel
    • 7.5.9. Rest of LAMEA Age Related Macular Degeneration Market
      • 7.5.9.1. Market Size and Forecast, By Drug Type
      • 7.5.9.2. Market Size and Forecast, By Disease Type
      • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Regeneron Pharmaceuticals Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Novartis AG
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. F. Hoffmann-La Roche Ltd.
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Biogen
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Bayer AG
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Coherus Biosciences Inc
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Sanofi
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Apellis Pharmaceuticals
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Bausch Health Companies Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Ionis Pharmaceuticals, Inc
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments